Source: Annual Congress 2009 - Airway cell biology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Kobayashi, N. Mercado, A. Miller-Larsson, P. J. Barnes, K. Ito (London, United Kingdom; Lund, Sweden). Protein phosphatase PP2A activation by formoterol reverses corticosteroid insensitivity. Eur Respir J 2009; 34: Suppl. 53, 3355

Member's Comments

No comment yet.

Related content which might interest you: Formoterol restores oxidative stress-induced corticosteroid insensitivity via activation of protein phosphatase PP2A Source: Annual Congress 2012 - Cellular signalling mechanisms in the airways Year: 2012 Activated protein phosphatase PP2A by formoterol enhances nuclear translocation of glucocorticoid receptor induced by budesonide Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via activation of protein phosphatase PP2A Source: Annual Congress 2011 - Phagocytes and dendritic cells Year: 2011 A novel target of formoterol, a dual-specificity phosphatase DUSP4 on regulation of corticosteroid budesonide sensitivity Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011 Impaired protein tyrosine phosphatase PTPRR reduces response to corticosteroid in mononuclear cells Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013 Long-acting beta2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013 Corticosteroid insensitivity and enhanced mitogen-activated protein kinase activity in airway smooth muscle cells of severe asthma Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010 Corticosteroids: use and insensitivity in severe asthma Source: Eur Respir Mon 2011; 51: 236-252 Year: 2011 PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Modulation of bradykinin (BK)-induced lung fibroblast proliferation and differentiation by budesonide (Bud) and formoterol (Form) involves the inhibition of ERK1/2 phosphorylation and Ca2+ mobilization Source: Annual Congress 2009 - Translational models of lung disease Year: 2009 MAP kinase phosphatase 1 mediates glucocorticoid inhibition of CD38 expression in human airway smooth muscle Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008 Oxidative stress-induced corticosteroid insensitivity is reversed by formoterol via inhibition of PI3K signalling in peripheral blood mononuclear cells from patients with COPD and severe asthma Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 Inhibition of inflammatory gene expression by dexamethasone partly depends on the phosphatase, MKP-1 (DUSP1) Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10 Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 JAK inhibitors overcome corticosteroid insensitivity in COPD Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 Role of protein phosphatase 1 glycogen-associated regulatory subunit in asthma Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 CREB signaling and chromatin remodeling during corticosteroid and theophylline therapy of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 355s Year: 2007 Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018